Antibiotic use, certain gut bacteria affect CAR-T efficacy, toxicity

Antibiotic use, certain gut bacteria affect CAR-T efficacy, toxicity - Blog

Researchers examined two cohorts of patients who received CD19-directed CAR-T cells for non-Hodgkin’s lymphoma or B-cell acute lymphoblastic leukemia. The researchers used the first cohort to retrospectively examine the impact of prior antibiotic use on CAR-T clinical outcomes. The second cohort had prospective baseline fecal samples collected before CAR-T cell infusion for subsequent assessment of […]

Dual-target CAR-T ‘very promising’ for advanced multiple myeloma

Dual-target CAR-T ‘very promising’ for advanced multiple myeloma - Blog

GC012F (Gracell Biotechnologies) is an autologous, genetically engineered, bispecific CAR-T that targets B cell maturation antigen (BCMA) and CD19 proteins on the surface of cancer cells. BCMA is universally expressed on malignant plasma cells and is a well-established target for multiple myeloma, while CD19 is expressed on both myeloma cells and their progenitor cells. The […]

Blood-brain barrier–penetrating single CRISPR-Cas9 nanocapsules for effective and safe glioblastoma gene therapy

Blood-brain barrier–penetrating single CRISPR-Cas9 nanocapsules for effective and safe glioblastoma gene therapy - Blog

Many drugs cannot cross the blood-brain barrier (BBB), which also applies to most CRISPR-carrying vehicles. So Bingyang Shi made chemically functional nanocapsules to penetrate the BBB, according to a study recently published in Science Advances. He essentially packaged unique CRISPR-Cas9/sgRNA complexes in a coating consisting of a thin polymeric shell made of positively charged guanidine […]

Dual-target CAR-T ‘very promising’ for advanced multiple myeloma

Dual-target CAR-T ‘very promising’ for advanced multiple myeloma - Blog

GC012F is an autologous, genetically engineered, bispecific CAR-T that targets B-cell maturation antigen and CD19 proteins on the surface of cancer cells. The new cell therapy, which has previously received FDA orphan drug designation, is manufactured within 24 hours of apheresis using Gracell’s proprietary FasT CAR platform. A single dose of an investigational chimeric antigen […]

Potentiating adoptive cell therapy using synthetic IL-9 receptors

Potentiating adoptive cell therapy using synthetic IL-9 receptors - Blog

Researchers have shown that a synthetic IL-9 receptor allows anti-cancer T cells to do their job without the need for chemo or radiation. T cells modified with the synthetic IL-9 receptor were potent against tumours in mice, as published in Nature. This group of researchers were interested in testing modified versions of the synthetic receptor […]

PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | NEJM

PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | NEJM - Blog

Breakthrough findings were presented at the 2022 ASCO Annual Meeting and published in The New England Journal of Medicine by researchers at Memorial Sloan Kettering Cancer Center (MSK) confirming a clinical complete response in all 14 patients who received the immunotherapy treatment dostarlimab as a first-line treatment for mismatch repair-deficient (MMRd) locally advanced rectal cancer. This new approach of “immunoablative” […]